Urticarial vasculitis - Urtikarial Vaskilit
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
References
Urticarial vasculitis se yon kondisyon ki ra ki make pa epizòd itikè ki dire lontan oswa ki repete. Pandan ke sentòm po li yo ka sanble ak itikè kwonik, yo inik paske itikè yo kole alantou pou omwen 24 èdtan epi yo ka lakòz tach nwa apre fennen. Menmsi souvan nan kòz enkoni, li ka pafwa deklanche pa sèten medikaman, enfeksyon, maladi otoiminitè, maladi san, oswa kansè. Gen kèk etid ki menm lye li ak COVID-19 ak grip H1N1. Li kapab tou afekte lòt pati nan kò a tankou misk, ren, poumon, vant, ak je. Pandan ke yon sèten kalite egzamen tisi ka konfime dyagnostik la, li pa toujou nesesè. Tretman anjeneral kòmanse ak antibyotik, dapsone, kolchisin, oswa idroksiklorokin pou ka ki pi modere. Pou ka ki pi grav, dwòg ki siprime sistèm iminitè a tankou methotrexate oswa kortikoterapi yo ta ka bezwen. Dènyèman, terapi byolojik (rituximab, omalizumab, interleukin-1 inhibitors) te montre pwomès pou ka difisil.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.
Yon nonm 35-zan te vini ak yon istwa 15-jou nan wouj klere, gratèl ki fè mal sou tou de kwis ak janm, ansanm ak doulè nan jwenti. Li te gen yon enfeksyon nan aparèy urin pou yon semèn anvan gratèl la parèt. Po l 'te montre plizyè sansib, bag ki gen fòm, pasyèlman blanch, plak wouj sou tou de bò kwis li ak janm li. Li te bay oral prednisolone (40mg / jou) pou yon semèn ansanm ak yon antihistamin ki pa somnolans (fexofenadine) . Nan yon semèn, tout gratèl yo disparèt nèt. Pa te gen okenn erupsyon plis pandan 6 mwa pwochen yo nan tcheke-ups regilye.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.
○ Tretman - Medikaman OTC
Si ou gen yon lafyèv (ogmante tanperati kò), nou rekòmande pou w chèche swen medikal pi vit posib.
Yo ta dwe sispann dwòg la sispèk. (egzanp antibyotik, dwòg anti-enflamatwa ki pa esteroyid)
Antihistamin oral tankou cetirizine oswa loratadine pou demanjezon.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]
Odè esteroyid OTC yo ka efikas pou pisans ki ba. Bezwen aplike pou plis pase yon semèn pou wè amelyorasyon.
#Hydrocortisone ointment